Evidence map›Paper›PMID 40779151›Full record

ArticleJournal of molecular histology2025

Exploring mechanisms of radiation-induced myocardial fibrosis using HMGB1 neutralizing antibody.

Gang Wang, Bi-Bo Wu, Sha-Sha Zhao, Jing Zhang, Yu Wang, Yin-Xiang Hu, Jun Wan, Bing Lu, Sheng-Fa Su

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Gang WangDepartment of Oncology, Affiliated Hospital of Guizhou Medical University, 28 Guiyi Street, Guiyang, 550001, Guizhou, China.
Bi-Bo WuDepartment of Oncology, Affiliated Hospital of Guizhou Medical University, 28 Guiyi Street, Guiyang, 550001, Guizhou, China.
Sha-Sha ZhaoDepartment of Oncology, Affiliated Hospital of Guizhou Medical University, 28 Guiyi Street, Guiyang, 550001, Guizhou, China.
Jing ZhangDepartment of Oncology, Affiliated Hospital of Guizhou Medical University, 28 Guiyi Street, Guiyang, 550001, Guizhou, China.
Yu WangDepartment of Oncology, Affiliated Hospital of Guizhou Medical University, 28 Guiyi Street, Guiyang, 550001, Guizhou, China.
Yin-Xiang HuDepartment of Oncology, Affiliated Hospital of Guizhou Medical University, 28 Guiyi Street, Guiyang, 550001, Guizhou, China.
Jun WanDepartment of Oncology, Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, 550000, China.
Bing LuDepartment of Oncology, Affiliated Hospital of Guizhou Medical University, 28 Guiyi Street, Guiyang, 550001, Guizhou, China.
Sheng-Fa SuDepartment of Oncology, Affiliated Hospital of Guizhou Medical University, 28 Guiyi Street, Guiyang, 550001, Guizhou, China. shengfasu_ssf@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveRadiation-induced myocardial fibrosis (RIMF) significantly impacts the long-term quality of life and non-tumor mortality in patients undergoing thoracic tumor radiotherapy. Despite its clinical significance, the mechanisms underlying RIMF formation remain inadequately understood, highlighting the importance of investigating its pathological mechanisms and identifying potential intervention targets.

methodsAn RIMF model was established in C57BL/6 mice, with interventions administered via subcutaneous intraperitoneal injections of HMGB1 neutralizing antibody (HMNA). The validity of the RIMF model and the effects of HMNA intervention were evaluated using hematoxylin and eosin (HE), Masson's trichrome staining, and echocardiography. Additionally, western blot, qPCR, ELISA, CCK8 assay, and tissue immunofluorescence were employed to investigate the relationship between radiation and cardiac injury, as well as the role of HMGB1 in RIMF formation, both in vitro and in the C57BL/6 mouse model.

resultsHE and Masson's trichrome staining, coupled with echocardiographic assessments, demonstrated that the early phase HMNA intervention group (RT + HMNA) exhibited significantly reduced cardiac tissue damage and fibrosis, and improved cardiac function compared to the radiation treatment group (RT). Experiments conducted on cardiomyocytes (H9C2) and in the mouse model, utilizing western blot, qPCR, ELISA, and tissue immunofluorescence demonstrated that radiation induced a substantial release of HMGB1 from cardiomyocytes into the extracellular space and triggered overexpression of the membrane receptor TLR4. Western blot analysis demonstrated that the hearts of the RT group exhibited significantly elevated levels of TLR4, NF-κB, PAI-1, and collagen I compared to the control group. In contrast, these levels were significantly lower in the RT + HMNA group. CCK8 assay results indicated that the proliferation activity of myofibroblasts was significantly higher in the active HMGB1 culture group (DMEM + HMGB1) than in the group without HMGB1 (DMEM).

conclusionEarly phase HMNA intervention during radiation exposure can effectively reduce fibrosis in RIMF, thereby improving cardiac function. Radiation induces cardiomyocytes to release substantial amounts of HMGB1 into the extracellular space. HMGB1 likely mediates the formation of RIMF through the HMGB1/TLR4/NF-kB/PAI-1 pathway in target cells and promotes myofibroblast proliferation.

Indexed as

Antibodies, NeutralizingCardiomyopathiesHMGB1 ProteinMyocardiumAnimalsDisease Models, AnimalFibrosisMaleMiceMice, Inbred C57BLMyocytes, CardiacNF-kappa BSignal TransductionToll-Like Receptor 4Antibodies, NeutralizingHMGB1 ProteinHMGB1 protein, mouseNF-kappa BToll-Like Receptor 4CancerCardiotoxicityHMGB1Myocardial fibrosisRadiation therapyToll-like receptor 4 (TLR4)

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.